<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">MUSCAT, JOSHUA E.</style></author><author><style face="normal" font="default" size="100%">DYER, ANNE-MARIE</style></author><author><style face="normal" font="default" size="100%">ROSENBAUM, RAPHAEL E.</style></author><author><style face="normal" font="default" size="100%">RIGAS, BASIL</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Nitric Oxide-releasing Medications and Colorectal Cancer Risk: The Framingham Study</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4471-4474</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><issue><style face="normal" font="default" size="100%">6C</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The major sources of human exposure to nitric oxide (NO) are medicinal nitrovasodilators that release NO into the vasculature. Experimental NO-donating aspirin also releases NO in a similar manner, and is a potent in vitro inhibitor of colon cancer. Materials and Methods: The effects of nitrovasodilators on the risk of colorectal cancer was studied in the Framingham Heart and Offspring studies among 145 cases of colorectal cancer and 433 matched controls. Results: Eleven percent of controls reported currently using nitroglycerine or other long-lasting nitrates. In conditional logistic regression analysis, the odds ratio (OR) for colorectal cancer associated with nitrovasodilator use was 1.2 (95% confidence interval [CI] 0.6, 2.2). In subgroup analysis, the OR was 0.7 (95% CI 0.2, 2.2) in aspirin users and 1.6 (95% CI 0.8, 3.2) in subjects not taking aspirin. Conclusion: These data indicate that NO does not change the risk of colorectal cancer. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>